GenoFocus (Korea) Today
| 187420 Stock | 4,050 165.00 3.91% |
Performance6 of 100
| Odds Of DistressLess than 27
|
GenoFocus is trading at 4050.00 as of the 29th of November 2024, a 3.91 percent decrease since the beginning of the trading day. The stock's open price was 4215.0. GenoFocus has about a 27 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for GenoFocus are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Moving against GenoFocus Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
GenoFocus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. GenoFocus' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding GenoFocus or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Materials, Chemicals (View all Sectors) |
GenoFocus (187420) is traded on KOSDAQ in Korea and employs 67 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 132.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GenoFocus's market, we take the total number of its shares issued and multiply it by GenoFocus's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. GenoFocus has 21.54 M outstanding shares.
GenoFocus has accumulated about 25.11 B in cash with (2.39 B) of positive cash flow from operations.
Check GenoFocus Probability Of Bankruptcy
Ownership AllocationGenoFocus has a total of 21.54 Million outstanding shares. GenoFocus secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check GenoFocus Ownership Details
GenoFocus Risk Profiles
Although GenoFocus' alpha and beta are two of the key measurements used to evaluate GenoFocus' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.55 | |||
| Semi Deviation | 3.73 | |||
| Standard Deviation | 6.77 | |||
| Variance | 45.85 |
GenoFocus Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in GenoFocus without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
GenoFocus Corporate Executives
Elected by the shareholders, the GenoFocus' board of directors comprises two types of representatives: GenoFocus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GenoFocus. The board's role is to monitor GenoFocus' management team and ensure that shareholders' interests are well served. GenoFocus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GenoFocus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Other Information on Investing in GenoFocus Stock
GenoFocus financial ratios help investors to determine whether GenoFocus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GenoFocus with respect to the benefits of owning GenoFocus security.